Baxter Announces Exclusive Distribution Agreement With bioM?rieux for Novel Acute Kidney Injury Diagnostic Test in Europe and U.S.
Sep 16, 2020
- Reinforces Baxter?s commitment to purposeful innovation that supports broader acute kidney injury (AKI) management to improve patient outcomes
- Combines Baxter?s global leadership in blood purification and focus on advancing patient-centered care with bioM?rieux?s global leadership in diagnostics
- Recent study highlights role of biomarker in predicting persistent severe AKI
1?Siew ED, Davenport A: The growth of acute kidney injury: a rising tide or just closer attention to detail? Kidney Int 2015;87:46-61. 2?O?Connor ME, Kirwan CJ, Pearse RM, Prowle JR: Incidence and associations of acute kidney injury after major abdominal surgery. Intensive Care Med 2016;42:521-530. 3?Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I, Jaber BL: World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol 2013;8:1482-1493. 4?Chawla LS, Bellomo R, Bihorac A, et al. Acute Disease Quality Initiative W (2017) Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol 13(4):241?257.?https://doi.org/10.1038/nrneph.2017.2 5?Kidney International Supplement (2011). 2012 Mar; 2(1): 19?36. 6?Hoste E, Bihorac A, Al-Khafaji, A, et al. Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study. Intensive Care Med 46, 943?953 (2020).?https://doi.org/10.1007/s00134-019-05919-0 7?Mandrekar, Jayawant N. Receiver Operating Characteristic Curve in Diagnostic Test Assessment. Journal of Thoracic Oncology 2010;5:1315-1316.
View source version on?businesswire.com:?https://www.businesswire.com/news/home/20200916005267/en/
Media Contact Andrea Johnson, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3020 Source: Baxter International Inc.